Targeting HER2(+) breast cancer: the TBK1/IKKε axis

HER2(+) breast cancer (BC) is a highly aggressive subtype, affecting ~20% of BC patients. Current treatments include adjuvant or neoadjuvant chemotherapy plus anti-HER2 agents such as trastuzumab, a monoclonal antibody directed against HER2. Despite improvement in disease free survival, most patient...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncoscience
Hoofdauteurs: Jiang, Zhe, Liu, Jeff C., Chung, Philip E.D., Egan, Sean E., Zacksenhaus, Eldad
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Impact Journals LLC 2014
Onderwerpen:
Research Perspective
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4278282/
https://ncbi.nlm.nih.gov/pubmed/25594009
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items